Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
MADRID — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead of switching to another androgen receptor pathway inhibitor (ARPI), a randomized trial showed. In patients with prior progression on an ARPI, median rPFS increased from 5.9 months with another ARPI […]
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
MADRID — Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor, a phase III trial demonstrated. Final progression-free survival (PFS) analysis showed a 26% reduction in disease progression or death with belzutifan versus everolimus (Afinitor), despite an […]
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC
MADRID — First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two phase III trials presented here. In the LIBRETTO-531 trial, selpercatinib resulted in superior progression-free survival (PFS) and treatment failure-free survival (TFFS) compared with the […]
Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer
MADRID — Chemotherapy’s generation-long dominance in first-line advanced urothelial cancer ended with a resounding victory for the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) in an international randomized trial. Overall survival (OS) and progression-free survival (PFS) doubled with enfortumab-pembrolizumab (EV-P) at 12.5 and 31.5 months versus 6.3 and 16.1 months with platinum-containing chemotherapy. […]
Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer
MADRID — Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, according to the DUO-E trial. The trial assessed the combination of durvalumab (Imfinzi) and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus the PARP inhibitor olaparib (Lynparza) or durvalumab […]
Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]
Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer
MADRID — Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative patients, the randomized KEYNOTE-811 trial showed. In patients receiving standard chemotherapy plus trastuzumab, median PFS improved from 8.1 months with placebo to 10.0 months with pembrolizumab (HR 0.73, […]